Coeptis Therapeutics (NASDAQ:ZSQR) Shares Up 7.2% – Here’s Why
by Sarita Garza · The Markets DailyCoeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR – Get Free Report) traded up 7.2% on Tuesday . The stock traded as high as $10.85 and last traded at $10.81. 73,918 shares changed hands during trading, a decline of 27% from the average session volume of 101,058 shares. The stock had previously closed at $10.08.
Coeptis Therapeutics Price Performance
The firm has a 50 day moving average price of $11.91 and a two-hundred day moving average price of $13.10. The company has a market cap of $547.73 million, a P/E ratio of -4.23 and a beta of -0.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25.
Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The business had revenue of $0.11 million during the quarter.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in ZSQR. Steward Partners Investment Advisory LLC lifted its position in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the last quarter. Yorkville Advisors Global LP bought a new stake in Coeptis Therapeutics during the third quarter worth about $140,000. Marshall Wace LLP bought a new position in shares of Coeptis Therapeutics during the 4th quarter valued at about $259,000. State Street Corp raised its holdings in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares in the last quarter. Institutional investors own 13.88% of the company’s stock.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.